Colby Pharmaceutical Co.

Executive Summary

Colby Pharmaceutical aims to develop drugs capable of inhibiting key enzymatic and hormonal signaling pathways in prostate and brain cancers. The start-up hopes to help men who have been diagnosed with primary or recurrent prostate cancer, including those who have failed current standard of care hormone therapy or chemotherapy. The company's lead compound is an anti-inflammatory and anti-androgenic small molecule that binds the androgen receptor. In culture and in animals, Colby says that it is therapeutic for androgen-dependent prostate tumors. The molecule does not appear to be pro-estrogenic and CPC-100 is also therapeutic for androgen-independent prostate tumors-which would distinguish it from all other anti-androgens now on the market.